Ligand Pharmaceuticals Inc.

473 articles with Ligand Pharmaceuticals Inc.

• Ligand to Report Second Quarter 2018 Results on August 6th

  7/9/2018

  Ligand Pharmaceuticals Incorporated announced plans to report second quarter 2018 financial results on August 6, 2018.

• Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement

  6/27/2018

  Updates 2018 Full Year and Second Quarter Financial Guidance

• Ligand to Participate in Upcoming Investor Conferences

  5/11/2018

  Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.

• Ligand to Report First Quarter 2018 Results on May 8th

  4/24/2018

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2018 financial results on May 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

• Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies

  3/30/2018

  venBio’s portfolio companies will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.

• 

  Roivant Licenses Diabetes Drug From Ligand Pharma

  3/7/2018

  Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.

• Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences

  3/6/2018

  Ligand Pharmaceuticals Inc. announced the signing of a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize LGD-6972, Ligand’s glucagon receptor antagonist (GRA).

• Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st

  2/6/2018

  Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

• Ligand Enters into Worldwide OmniAb Platform License Agreement with Ferring Pharmaceuticals

  1/22/2018

  Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.

• Ferring Enters Into Worldwide OmniAb Platform License Agreement With Ligand

  1/22/2018

  Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology.

• Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging

  1/19/2018

  The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals.

• Ligand Enters into Worldwide OmniAb Platform License Agreement with Glenmark Pharmaceuticals

  1/11/2018

  Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken, OmniRat, OmniMouse and OmniFlic to discover fully human mono- and multispecific antibodies.

• Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects

  1/3/2018

  Under the license agreements with HanAll, Ligand is eligible to receive milestones and royalties on the successful development of antibodies and to share sub-license revenue on out-licensed antibodies.

• 

  Why This Small SoCal Biotech's Pipeline Makes it Flushed for Growth

  11/29/2017

  Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone's interested in fast-growing stocks.

• Ligand Provides Highlights from Today’s Analyst Day Event - Nov. 15, 2017

  11/14/2017

  The webcast is available at www.ligand.com.

• Ligand Reports Third Quarter 2017 Financial Results

  11/10/2017

  Total revenues for the third quarter of 2017 were $33.4 million, compared with $21.6 million for the same period in 2016.

• Ligand to Report Third Quarter 2017 Results on November 9th

  10/25/2017

  Ligand Pharmaceuticals Incorporated announced today that it plans to report third quarter 2017 financial results after market close on November 9, 2017 and to provide additional commentary during its Analyst Day.

• 

  3 High Potential Low Risk Biotechs Investors Should Watch Out For

  10/24/2017

  When you think about it, most small biotech companies are odd investments.

• Ligand Scoops Up Bay Area's Crystal Bioscience In $25 Million Cash Plus Additional Potential Payments Deal

  10/5/2017

• Ligand To Host Analyst Day On November 14th In New York City

  9/25/2017